Monofer® launched in Germany

October 25, 2011

Pharmacosmos A/S, Denmark, announced today the launch of the company's product Monofer® in Germany. The Danish company has entered into collaboration with Medice Pharma GmbH & Co. in Iserlohn, Germany.

The German company is responsible for the marketing of Monofer® in Germany and joins Pharmacosmos' line of trusted partners. 

Lars Christensen, MD, President and CEO of Pharmacosmos, said: "We are delighted to team up with Medice as our partner for Monofer® in Germany and we look forward to the collaboration. Medice is a highly professional company specialized in the treatment of anaemia." 

Richard Ammer, MD, PhD, General Manager of Medice, said: "Patients suffering from iron deficiency anaemia will benefit from fast high dose therapy, which will result in fewer hospital visits for patients. Monofer® offers high dose opportunities in a single administration and we believe Monofer® will become a very important product in the treatment of iron deficiency anaemia in Germany."

Monofer® (iron isomaltoside 1000) is an intravenous iron compound based on an innovative chemical structure. Monofer® is indicated for treatment of iron deficiency anaemia and offers high dose administration up to 20mg/kg in 15-60 minutes. Monofer® offers most patients a full iron correction in just one visit and no test dose is required. Iron deficiency anaemia is a global health problem and Monofer® has the potential to cure millions of patients world-wide. 

Monofer® is registered in several countries and is currently available in UK, Ireland, Denmark, Sweden, Norway, Finland, Netherlands, Germany and Poland.

Further information
Lars Christensen, MDPresident and CEO
T: +45 59 48 59 59

Richard Ammer, MD, PhDGeneral Manager
T: +49 2371 937-0

About Medice Pharma GmbH & Co.
Medice is based in Iserlohn, Germany, and is a fully-integrated, mid-sized family-owned pharmaceutical enterprise. The company develops, manufactures and distributes high-quality drugs, pharmaceutical products and medical devices throughout Germany, Europe and key international markets and holds leading positions in defined niche indications. Likewise, Medice has a broad portfolio for patients with renal insufficiency and is the first supplier with Epoetin and iron to treat anemia.

About Pharmacosmos A/S

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.